AP Biosciences, Inc. Share Price

6945

TW0006945009

Biotechnology & Medical Research

End-of-day quote Taipei Exchange 02/09/2026			5-day change	1st Jan Change
97.60 ^TWD	+1.14%		-2.40%	-45.78%

08-12	AP Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-15	AP Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Valuation : AP Biosciences, Inc.

Market Cap	9.47B 298M 257M 242M 221M 412M 28.15B 416M 2.87B 1.11B 14.39B 1.12B 1.09B 47.28B	P/E 2024	-8.86x	P/E 2025	-34.4x
Enterprise Value	8.36B 263M 227M 214M 195M 364M 24.85B 367M 2.53B 982M 12.7B 988M 966M 41.73B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	52.56%	Yield 2024 *	-	Yield 2025	-

* Estimated data More valuation ratios

Latest news : AP Biosciences, Inc.

08-12	AP Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-15	AP Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-12	Delos Capital and AP Biosciences Inc. Launch Collaboration to Create New Biotech Companies Focused on Next-Generation Antibodies	CI
03-31	AP Biosciences, Inc. has filed an IPO in the amount of TWD 1.2562 billion.	CI
03-23	AP Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-22	AP Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
12/08/25	AP Biosciences, Inc. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
14/05/25	AP Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
29/04/25	AP Biosciences Presents Preclinical Data on P95her/Cd137 T-Cell Engager At American Association of Cancer Research Annual Meeting	CI
22/04/25	AP Biosciences Doses First Patient In Phase 1/2 Clinical Trials Of AP402 For HER2+ Cancer Patients	RE
22/04/25	AP Biosciences Doses First Patient in Phase 1/2 Clinical Trials of AP402 for HER2+ Cancer Patients	CI
21/04/25	AP Biosciences to Present New Preclinical Data at American Association of Cancer Research Annual Meeting	CI
13/08/24	AP Biosciences Inc Reports Earnings Results for the Half Year Ended June 30, 2024	CI

More news

Press Releases : AP Biosciences, Inc.

24/07/25

Designing antibodies to think before they bind

More press releases

Managers and Directors : AP Biosciences, Inc.

Manager	Title	Age	Since
Jeng-Horng Her CEO	Chief Executive Officer	-	26/05/2013
Shu Cheng Lin DFI	Director of Finance/CFO	-	17/10/2022
Wan Ju Tseng ADM	Chief Administrative Officer	-	17/10/2022

Director	Title	Age	Since
Jeng-Horng Her BRD	Director/Board Member	-	08/11/2022
Ming-Tain Lai BRD	Director/Board Member	-	03/06/2019
Hui Chin Tseng BRD	Director/Board Member	-	03/06/2021

More insiders

AP Biosciences Inc is a Taiwan-based company mainly engaged in the research and development of protein drugs and antibody drugs. The Company develops early candidate drugs and preclinical trials, and develops different monoclonal or bispecific antibody drugs for potential targets, mechanisms of action, and disease characteristics through drug design and existing technology platforms. The Company's technology platform and bispecific protein drug research and development projects include IBI302-anti-vascular endothelial growth factor (VEGF) and anti-complement bifunctional recombinant protein, OmniMab fully human antibody library, AP505-PD-L1 x VEGF bispecific antibody, target-directed T cell activation 3T platform (T-cube), AP203-PD-L1 x CD137 fully human bispecific antibody, and others.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
02/09/26	NT$97.60	+1.14%	122,994
01/09/26	NT$96.50	-1.83%	327,248
31/08/26	NT$98.30	-5.48%	472,027
28/08/26	NT$104.00	-2.80%	171,712
27/08/26	NT$107.00	+5.42%	608,366

End-of-day quote Taipei Exchange

More quotes

Stock Market
Stocks
6945 Stock

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

1 day	+1.14%
1 week	-2.40%
Current month	-0.71%
1 month	+11.93%
3 months	-22.85%
6 months	-44.86%
Current year	-45.78%

1 week	95	109
1 month	86.4	116.5
Current year	86.1	236
1 year	86.1	236
3 years	36.3	236
5 years	36.3	236
10 years	36.3	236

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AP BIOSCIENCES, INC.	+1.14%	-2.40%	-19.34%	+82.43%	295M
WUXI APPTEC CO., LTD.	+1.03%	-3.11%	+39.80%	+94.60%	68.21B
ARGENX SE	+1.62%	+0.33%	+48.61%	+88.33%	64.25B
INSMED INCORPORATED	+4.21%	+1.80%	-12.85%	+459.32%	26.54B
BIONTECH SE	+1.83%	-7.77%	+3.17%	-14.74%	25.61B
GENMAB A/S	+1.30%	-0.96%	+32.58%	-17.99%	19.88B
PHARMAESSENTIA CORPORATION	-0.38%	-12.42%	+224.86%	+373.18%	17.13B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.65%	-5.83%	+1.44%	+544.44%	14.93B
EXELIXIS, INC.	+2.88%	+4.33%	+57.42%	+157.39%	14.1B
MADRIGAL PHARMACEUTICALS, INC.	+1.53%	+1.49%	+25.41%	+195.41%	12.45B
Average	+1.58%	-3.89%	+40.11%	+196.24%	26.34B
Weighted average by Cap.	+1.60%	-2.71%	+42.60%	+162.42%

	2024	2025
Net sales	-	-
Net income	-423M -13.31M -11.48M -10.82M -9.85M -18.42M -1.26B -18.56M -128M -49.7M -643M -49.98M -48.88M -2.11B	-445M -14M -12.08M -11.38M -10.37M -19.38M -1.32B -19.52M -135M -52.28M -676M -52.58M -51.43M -2.22B
Net Debt	-1.47B -46.3M -39.94M -37.63M -34.28M -64.08M -4.37B -64.56M -445M -173M -2.24B -174M -170M -7.35B	-1.11B -34.99M -30.18M -28.43M -25.91M -48.43M -3.31B -48.79M -337M -131M -1.69B -131M -129M -5.55B

AP Biosciences, Inc. Share Price

Stocks

6945

TW0006945009

Biotechnology & Medical Research

Valuation : AP Biosciences, Inc.

Chart: AP Biosciences, Inc.

Latest news : AP Biosciences, Inc.

Press Releases : AP Biosciences, Inc.

Quotes and Performance

Price Extremes

Managers and Directors : AP Biosciences, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes